Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT06182683
Recruiting Not applicable

Concurrent OCT and FFR-guided PCI in CAD

NCT06182683 · tracked via the Priya Life Science South Korea tracker
Sponsor
Korea University Guro Hospital
Phase
Not applicable
Started
2023-11-30
Last updated
2026-09-30

Condition(s) studied

Coronary Artery DiseaseImageAtheroscleroses, Coronary

Investigational drug(s) / intervention(s)

optical coherence tomography and fractional flow reserveCoronary angiography

optical coherence tomography and fractional flow reserve: The assessment of pre-procedural lesions and optimization status of implanted stents will involve both intracoronary imaging and physiological indices.

Coronary angiography: The assessment of pre-procedural lesions and optimization status of implanted stents will be determined by conventional coronary angiography

Study summary

The present study is a prospective randomized clinical trial aimed to compare the therapeutic strategy of angiography-guided versus concurrent OCT/FFR-guided intervention in patients with coronary artery disease.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age greater than 19 years old 2. Patients undergoing coronary stent implantation for stable angina or acute coronary syndrome 3. Patients provided on informed consent Exclusion Criteria: 1. Individuals with a history of increased bleeding tendencies or hematologic disorders 2. Presented with refractory cardiogenic shock 3. Individuals with a history of stent thrombosis 4. Expected life expectancy of less than 1 year 5. Left ventricular ejection fraction (LVEF) ≥ 20% 6. Women who are breastfeeding, pregnant, or planning to become pregnant 7. Deemed unsuitable for participation by the investigator 8. Patients unwilling to participate in the clinical trial

Primary outcome measure(s)

  • Rate of target vessel failure (TVF) — 1-year
    a composite endpoint of cardiac death, target vessel-related non-fatal myocardial infarction, clinically driven-target vessel revascularization

Trial sites (1)

FacilityCityRegionStatus
Korea University Guro Hospital Seoul South Korea Recruiting

More Korea University Guro Hospital trials in South Korea

Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer Recruiting
Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance Recruiting
Comparison of Fractional FLOW Reserve Outcomes With Drug-Coated Balloon-Based Versus Drug-Eluting Stent-Only Percutaneous Coronary Intervention Strategies Starting soon
Impact of CES1 Genotype on Remimazolam Recruiting
OCT-Guided Stent Optimization for Short-Duration Dual Antiplatelet Therapy in Stable Angina Recruiting

Other trials for the same condition

Prospective Pecutaneous Coronary Intervention Registry Recruiting
AI-Powered Electrocardiography for Diagnosis and Prognostic Prediction in Cardiovascular Disease (AI-CVD): Multicenter Retrospective Study Recruiting
STabilization of Atheroma by Lipid-reducing Effect of Drug-Coated Balloon (STABLE-DCB) Recruiting
Evaluation of Effectiveness and Safety of Xience Skypoint Stents in Routine Clinical Practice Recruiting
The DECISION-CTO Extended 10 Y Follow-up Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06182683 on ClinicalTrials.gov ↗ ← All trials in South Korea